What is the role of albumin priming in hemodialysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Albumin Priming in Hemodialysis: Not Recommended

Intravenous albumin is not suggested for priming hemodialysis circuits, prevention or treatment of intradialytic hypotension, or improving ultrafiltration in patients undergoing kidney replacement therapy. 1

Guideline Recommendation

The 2024 International Collaboration for Transfusion Medicine Guidelines provides a conditional recommendation against albumin use in hemodialysis settings, based on very low certainty of evidence 1. This represents the highest quality and most recent guideline evidence available.

Evidence Base

Intradialytic Hypotension and Ultrafiltration

A Cochrane systematic review evaluated albumin for intradialytic hypotension treatment 1:

  • 5% albumin vs. saline (N=45): No difference in target ultrafiltration achieved or other clinical outcomes
  • 20% albumin studies: Small trials (N=10-20) suggested better blood pressure maintenance but no improvements in ultrafiltration or other meaningful outcomes
  • One 2021 trial (N=65) in hospitalized patients with albumin <30 g/L showed improved hypotension metrics with 25% albumin, but this represents a highly selected population

Circuit Priming Studies

Research specifically examining albumin priming shows no benefit:

  • A 2019 crossover study (N=10) using 3D CT scanning found no differences in dialyzer fiber patency between circuits primed with versus without albumin 2
  • The study tested both FX800 and Evodial dialyzers with albumin priming and found no improvement in fiber blocking

Heparin-Albumin Priming Context

Studies from 2013-2017 examined heparin-albumin priming specifically for anticoagulation reduction in bleeding-risk patients 3, 4:

  • These protocols used albumin (1 g/L) combined with heparin (5000 U/L) for priming, then discarded the priming solution
  • The benefit derived from heparin coating the circuit, not from albumin administration to the patient
  • This is a fundamentally different indication than albumin priming for hemodynamic support

Cost-Benefit Analysis

The guideline explicitly addresses economic considerations 1:

  • Annual cost: ~$20,000 per patient (USD) for 25g albumin given thrice-weekly
  • No demonstrated superiority over less costly alternatives
  • Given lack of mortality or morbidity benefit, cost cannot be justified

Preferred Alternative Strategies

Instead of albumin priming, prioritize these evidence-based approaches for intradialytic hypotension 1:

  1. Dialysate modifications:

    • Higher dialysate calcium concentration
    • Lower dialysate temperature

  2. Ultrafiltration optimization:

    • Individualized ultrafiltration rates
    • Avoid excessive fluid removal rates

  3. Pharmacologic options:

    • Midodrine (oral vasopressor) alone or combined with dialysate modifications

  4. Membrane selection:

    • For reduced anticoagulation settings, asymmetric triacetate (ATA) dialyzers outperform conventional polysulfone or heparin-coated membranes 2

Critical Caveats

Do not confuse albumin priming with:

  • Heparin-albumin priming for anticoagulation (where priming solution is discarded)
  • Albumin administration for volume resuscitation during dialysis
  • Treatment of hypoalbuminemia (also not recommended per guidelines 1)

Historical context: A 1982 study in septic ARF patients showed improved hemodynamic tolerance with 17.5% albumin priming 5, but this predates modern dialysis techniques and has not been replicated in contemporary practice.

Quality of Life Considerations

Intradialytic hypotension significantly impacts patient morbidity and mortality 1. However, albumin has not demonstrated improvement in patient-important outcomes including:

  • Symptom reduction
  • Treatment completion rates
  • Long-term cardiovascular outcomes
  • Quality of life measures

The guideline explicitly notes that further studies are needed to determine if albumin affects these patient-centered outcomes 1.

Implementation

Given the conditional recommendation against use, albumin priming should be reserved only for research protocols until higher-quality evidence emerges demonstrating benefit in mortality, morbidity, or quality of life outcomes.

References

3
Research

Heparin albumin priming in a clinical setting for hemodialysis patients at risk for bleeding.

Hemodialysis international. International Symposium on Home Hemodialysis, 2017

Related Questions

What is the appropriate dose and infusion rate of 5% albumin for a 3‑kg neonate, and how should it be monitored?
What is the proper method to dilute 20% albumin to obtain a 5% albumin solution using sterile technique?
What is the recommended method for administering albumin to neonates?
Is a serum albumin level of 4.7 g/dL within the normal range and does it require any intervention?
What is the appropriate albumin infusion protocol, including indications, dosing, and monitoring, for adult patients with clinically significant hypoalbuminemia or requiring plasma volume expansion?
How should anemia be managed in a patient with chronic liver disease and extrahepatic portal vein obstruction complicated by portal and superior mesenteric vein thrombosis and an indirect bilirubin of 2.5 mg/dL?
Is it safe for a patient with rheumatoid arthritis on disease‑modifying antirheumatic drugs, biologic agents, and low‑dose glucocorticoids to undergo dental implant surgery, and what pre‑operative and post‑operative precautions are recommended?
What is an appropriate inpatient intravenous antibiotic regimen for a 87-year-old female with impaired renal function (eGFR ~37 mL/min), significant bacteriuria, and a prior ESBL‑producing Escherichia coli urinary infection?
What are the recommended guidelines for fish‑oil (omega‑3) supplementation, including dosing, contraindications, and monitoring?
What are the guideline-recommended non‑HDL cholesterol target levels and treatment approach for preventing cardiovascular disease in adults based on risk categories?
In a patient with urinary tract infection, can co-amoxiclav (amoxicillin/clavulanate) cause persistent dysuria at the end of urination when the pathogen is resistant to the antibiotic?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.